NeOnc CEO Adds Another 70,000 Shares as Insider Buying Continues
The CEO’s reported beneficial ownership increased to approximately 7.77 million shares, including holdings through affiliated entities.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
NeOnc Technologies Holdings (NASDAQ:NTHI) CEO Amir Heshmatpour purchased another 70,000 common shares on November 5 and 6 for approximately $230,510. He bought 30,000 shares at a weighted average price of approximately $3.17 and 40,000 at approximately $3.39, respectively. His reported beneficial ownership rose to approximately 7.77 million shares, including affiliated-entity holdings.
The purchases follow a November 5 update disclosing that Heshmatpour and Thomas C. Chen had bought a combined 160,016 shares for approximately $629,000 following NEO100 Phase 2a results. Reported in August, that study met its primary endpoint: six-month progression-free survival, or survival without disease worsening, was 48.9% against a prespecified 20% benchmark (p=0.0047). Updated NEO100 data and Phase 1 findings for NEO212, an investigational central nervous system cancer therapy, are scheduled for presentation November 13 at the Society for Neuro-Oncology annual meeting.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Positive
- Major pointNEO100 Phase 2a met its primary endpoint: 48.9% six-month progression-free survival versus a prespecified 20% benchmark (p=0.0047).
- Minor pointCEO Amir Heshmatpour purchased 70,000 shares for approximately $230,510 on November 5 and 6.
- Minor pointEarlier disclosed insider purchases totaled 160,016 shares for approximately $629,000 by Heshmatpour and Thomas C. Chen.
Negative
- None.
Details
Market move: NTHI +7.19% vs previous close. CEO share purchase
On Nov 9, the day this news came out, the latest delayed price for NTHI is 7.19% above the previous close. Our momentum scanner has recorded 3 alerts for this stock so far that day. The latest delayed price is $3.74. Relative volume is exceptionally heavy at 5.2x what this stock usually trades by this time of day.
Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.
Key Figures
- CEO share purchase
- 70,000 shares
- Purchases on November 5 and 6
- Earlier insider purchases
- 160,016 shares
- Combined purchases disclosed in the November 5 quarterly update
- Six-month progression-free survival
- 48.9%
- NEO100 Phase 2a study
- Prespecified benchmark
- 20%
- NEO100 Phase 2a study comparison
- P-value
- p=0.0047
- NEO100 Phase 2a primary endpoint result
Historical Context
-
Reported earlier insider purchases alongside NEO100 Phase 2a results meeting its primary endpoint.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
form 4 regulatory
weighted average price financial
beneficial ownership financial
progression-free survival medical
idh1-mutant medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
DALLAS, Nov. 09, 2026 (GLOBE NEWSWIRE) -- (www.InvestorsTape.com) — NeOnc Technologies Holdings (NASDAQ:NTHI) CEO Amir Heshmatpour has purchased another 70,000 shares of the company's common stock for approximately
The transactions took place on November 5 and 6, with Heshmatpour purchasing 30,000 shares at a weighted average price of approximately
This is not an isolated show of confidence. Heshmatpour has repeatedly purchased shares in the open market during 2026, including purchases in August and September. In its November 5 quarterly update, NeOnc disclosed that Heshmatpour and fellow insider Thomas C. Chen had purchased a combined 160,016 shares for approximately
The latest purchases add another
NeOnc is developing NEO100, an intranasal treatment candidate for recurrent IDH1-mutant high-grade glioma, and NEO212, an investigational therapy for central nervous system cancers. The company reported in August that its NEO100 Phase 2a study met its primary endpoint, achieving six-month progression-free survival of
Updated NEO100 data and NEO212 Phase 1 findings are scheduled for presentation at the Society for Neuro-Oncology annual meeting on November 13.
About InvestorsTape.com
At InvestorsTape.com, our mission is simple: deliver financial news that cuts through the noise and shines a spotlight on the companies, innovations, and market forces shaping the next decade of growth. In a landscape dominated by high-frequency headlines and fleeting narratives, we bring clarity, depth, and balance to the stories that matter, helping investors discover high-potential companies and evaluate emerging opportunities with confidence.
Contact
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of applicable securities laws, including statements that may regard NeOnc Technologies Holdings’ future revenue, growth trajectory, profitability outlook, expansion plans, strategic partnerships, potential regulatory approvals, and other projections, plans, and objectives. Forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those expressed or implied, including market conditions, timing of venue openings, execution risks, operational performance, competition, regulatory matters, and general economic conditions. Readers should not place undue reliance on these statements, which speak only as of the date made.
General Disclaimer:
InvestorsTape.com has been compensated for press and editorial coverage of NeOnc Technologies Holdings and further disclosure information is available here. This communication is provided for informational and journalistic purposes only and reflects the independent editorial views of InvestorsTape.com.
This editorial discusses investigational therapy and clinical-trial results and is not medical advice or a recommendation to buy or sell securities. This publication is protected speech under the First Amendment of the United States Constitution. Nothing herein constitutes an offer, solicitation, or recommendation to buy or sell any security, nor should it be construed as investment advice. Investing in securities involves risk, including the possible loss of principal. Readers are encouraged to conduct their own due diligence and consult with a qualified financial advisor before making any investment decision.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did NeOnc’s NEO100 Phase 2a trial show?
The study met its primary endpoint, achieving six-month progression-free survival of 48.9% compared with a prespecified 20% benchmark (p=0.0047). NEO100 is an intranasal treatment candidate for recurrent IDH1-mutant high-grade glioma.